NDC product
Respiratory Relief
NDC 53499-5295 · Schwabe North America, Inc
Key facts
| Product NDC | 53499-5295 |
|---|---|
| Proprietary name | Respiratory Relief |
| Nonproprietary name | GUAIFENESIN |
| Substances | GUAIFENESIN |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Schwabe North America, Inc |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE] |
| Marketing start | Jul 29, 2025 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: